Sucampo Reports Third Quarter 2016 Financial Results
ROCKVILLE, Md., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today reported consolidated financial results for the third quarter ended September 30, 2016. The company also highlighted important corporate updates.
Key Updates
* Recently completed a settlement and license agreement with Dr. Reddy’s Laboratories, Ltd. and certain of its affiliates (Dr. Reddy’s) that resolves patent litigation in the United States related to Sucampo’s AMITIZA (lubiprostone) 8 mcg and 24 mcg soft gelatin capsules. The agreement provides for an entry date more than six years from today’s date and profit sharing on product sales by Dr. Reddy’s.
Key Updates
* Recently completed a settlement and license agreement with Dr. Reddy’s Laboratories, Ltd. and certain of its affiliates (Dr. Reddy’s) that resolves patent litigation in the United States related to Sucampo’s AMITIZA (lubiprostone) 8 mcg and 24 mcg soft gelatin capsules. The agreement provides for an entry date more than six years from today’s date and profit sharing on product sales by Dr. Reddy’s.